We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -6.86% | 1.90 | 1.84 | 1.96 | 2.01 | 2.00 | 2.00 | 1,925,128 | 16:35:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -1.76 | 6.7M |
TIDMIMM
Immupharma PLC
07 September 2012
FOR IMMEDIATE RELEASE 7 SEPTEMBER 2012
RNS REACH
ImmuPharma to Present at
Rodman and Renshaw Annual Global Investment Conference, New York
Tuesday 11 September 2012
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that it will be presenting at the Rodman and Renshaw Annual Global Investment Conference on Tuesday 11 September 2012 at the Waldorf Astoria in New York City. Tracy Weimar, Vice President, Operations and Finance will present an overview of ImmuPharma at 16:55 PM Eastern Time.
If you would like to arrange a one to one meeting with ImmuPharma during this conference between 10-12 September, please do not hesitate to contact either Tracy Weimar or Lisa Baderoon, Head of Investor Relations.
Ends
For further information please contact:
ImmuPharma PLC (www.immupharma.com) Tracy Weimar, Vice President, Operations and Finance tracy.weimar@immupharma.com +44 020 7152 4080 Lisa Baderoon, Head of Investor Relations Lisa.baderoon@immupharma.com +44 7721 413 496 Buchanan + 44 20 7466 5000 Mark Court
Notes to Editors
ImmuPharma
ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, Lupuzor(TM) a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSFFSWFESEFU
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
